Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195399 | 0.94 | GRK6 (0.49) | CNR2KMT2ASMN1; SMN2MEN1HTT | |
| SCHEMBL655214 | 0.87 | CNR2 (0.49) | CNR2GRK6EGFRERBB2SLC2A1 | |
| SCHEMBL7150414 | 0.85 | EGFR (0.47) | CNR2KMT2ASMN1; SMN2MEN1HTT | |
| SCHEMBL16689642 | 0.85 | SLC2A1 (0.49) | CNR2GRK6SLC2A1TSHRALDH1A1 | |
| SCHEMBL12056655 | 0.84 | EGFR (0.46) | CNR2KMT2ASMN1; SMN2MEN1HTT | |
| SCHEMBL3901022 | 0.84 | CNR2 (0.44) | CNR2GRK6EGFRERBB2 | |
| SCHEMBL80942 | 0.84 | CNR2 (0.44) | CNR2GRK6EGFRERBB2 | |
| SCHEMBL2139359 | 0.83 | CNR2 (0.44) | CNR2KMT2ASMN1; SMN2MEN1HTT | |
| SCHEMBL2138070 | 0.83 | CNR2 (0.44) | CNR2KMT2ASMN1; SMN2MEN1HTT | |
| SCHEMBL1305857 | 0.83 | CNR2 (0.44) | CNR2KMT2ASMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501172-B2 | Integrated recording and labeling with optical recording device | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2009-03-10 | — | — | US | claimed |
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | claimed |
| US-7172991-B2 | Integrated CD/DVD recording and labeling | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2007-02-06 | — | — | US | claimed |
| US-20060262178-A1 | Integrated recording and labeling with optical recording device | ANDERSON DARYL E | 2006-11-23 | — | — | US | claimed |
| EP-1687005-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20030108708-A1 | Integrated CD/DVD recording and labeling | HEWLETT-PACKARD DEVELOPMENT COMPANY L.P. | 2003-06-12 | — | — | US | claimed |
| US-20220372312-A1 | MARKING COMPOSITIONS | SANFORD L.P. | 2022-11-24 | — | — | US | disclosed |
| EP-4092089-A1 | MARKING COMPOSITIONS | Sanford, L.P. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-9797885-B2 | Methods and articles for the detection of exposure to polyhydroxyaromatic skin irritants | SeeLeaf Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9611409-B2 | Color developing colorless primer | OATEY CO. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160327546-A1 | METHODS AND ARTICLES FOR THE DETECTION OF EXPOSURE TO POLYHYDROXYAROMATIC SKIN IRRITANTS | SEELEAF INC | 2016-11-10 | — | — | US | disclosed |
| EP-0311926-A2 | Photopolymerisable composition | MORTON INTERNATIONAL, INC. (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4271251-A | LEUCO DYE, PHOTOOXIDIZER, 2,4-DIHYDROXY-BENZALDOXIME | FUJI PHOTO FILM CO., LTD. (JP) | 1981-06-02 | — | — | US | disclosed |
| US-4139390-A | Presensitized printing plate having a print-out image | EASTMAN KODAK COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
| US-4119466-A | MEROCYANINE DYES | EASTMAN KODAK COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4101326-A | Process for making stabilized polyesters used in radiation-sensitive compositions for lithographic plates having improved wear life including hindered phenols and phosphoric acid esters | EASTMAN KODAK COMPANY (US) | 1978-07-18 | — | — | US | disclosed |
| US-4062686-A | MEROCYANINE BENZOTHIAZOLINES OR BENZOSELENAZOLINES | EASTMAN KODAK COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | CNR2 2971/4885KMT2A 3377/4885SMN1; SMN2 3228/4885 |
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | HTR4, DRD4, SLC6A3 | CNR2 40/4885KMT2A 662/4885SMN1; SMN2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.